Martin Madaus joins Haemonetics board, bringing three decades of diagnostics experience to HAE

In focus for HAE: a board seat filled as of July 24, 2026, by Martin Madaus, a diagnostics and life sciences executive whose career spans more than 30 years at the C-suite level of major global health companies. The appointment was disclosed in an 8-K filing. What to watch next for Haemonetics Corporation (NYSE: HAE), headquartered in Boston, is how Madaus's commercial and operational background shapes board-level decisions across the company's Apheresis and MedSurg segments.

Who Martin Madaus is

The breadth of Madaus's operating history covers three prior chief executive roles. At Ortho Clinical Diagnostics (now known as QuidelOrtho Corporation), he served as Chairman and Chief Executive Officer and led the company's business turnaround following its carve-out from Johnson & Johnson. Corporate strategy, commercial growth, and operational restructuring were all in scope. Before Ortho, at Millipore Corporation, he held the title of Chairman, President and Chief Executive Officer and guided the company through a transformation that ended with Merck KGaA acquiring it in 2010. His earlier role was President and Chief Executive Officer of Roche Diagnostics North America.

Madaus has been Senior Operating Executive at The Carlyle Group since 2019, focusing on healthcare investment advisory and portfolio company performance. On the board side, he currently chairs the Board of Repligen Corporation and sits as a director of Azenta, Inc. His academic credentials include a Doctor of Veterinary Medicine from the University of Munich and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover, both in Germany.

What the board chair said

Ellen Zane, Chair of Haemonetics' Board of Directors, cited Madaus's record of leading complex global organizations and creating shareholder value as directly relevant to the company's current path. Zane's statement tied his background to two specific goals: executing the company's existing strategy and expanding its presence across targeted end markets.

The setup for HAE

Haemonetics operates two primary segments. Its Apheresis business uses proprietary technologies to improve safety, yield, donor satisfaction, and operational efficiency for plasma and blood collectors globally. The MedSurg segment runs two tracks: Blood Management Technologies, which help clinicians make treatment decisions and manage blood product use, and Interventional Technologies, which cover advanced vascular closure systems and sensor-guided tools aimed at improving procedural outcomes.

Board appointments rarely move the tape on their own. The next verifiable marker here is the proxy filing, where Madaus's election will appear alongside the broader director slate for shareholder ratification.